FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302299867> ?p ?o ?g. }

• W4302299867 endingPage "1006" @default.
• W4302299867 startingPage "999" @default.
• W4302299867 abstract "The use of biomarkers in spinal cord injury (SCI) research has evolved rapidly in recent years whereby most studies focused on the acute post-injury phase. Since SCI is characterized by persisting neurological impairments, the question arises whether blood biomarkers remain altered during the subacute post-injury time. Sample collection in the subacute phase might provide a better insight in the ongoing SCI specific molecular mechanism with fewer confounding factors compared with the acute phase where, amongst other complications, individuals receive a substantial amount of medication. This study aimed to determine if the temporal dynamics of serum biomarkers of neurodegeneration differ between individuals depending on their extent of neurological recovery in the transition phase between acute and chronic SCI. We performed a secondary analysis of biomarkers in patients with SCI (n = 41) who were treated at a level I trauma center in Germany. Patients with cervical or thoracic SCI regardless of injury severity were included. Blood samples were collected in the acute phase (1-4 days post-injury), and after 30 and 120 days post-injury. Serum protein levels of glial fibrillary acidic protein (GFAP) and neurofilament light protein (NfL) were determined for each time-point of sample collection using R-Plex Assays (Meso Scale Discovery). Linear mixed models were used to evaluate the trajectory of GFAP and NfL over time. Fixed effects of time, neurological recovery, and injury severity, along with the recovery-by-time interaction, were included in models with random slopes and intercepts. GFAP levels increase during the first days after SCI and decrease in subacute to chronic stages. Notably, the trajectory of GFAP over time is significantly associated with the extent of neurological recovery during the transition from acute to chronic SCI with a steeper decline in individuals who recovered better. Serum levels of NfL continue to rise significantly until Day 30 followed by a decrease afterwards, independent of neurological recovery. The trajectory of serum GFAP levels qualifies as a prognostic biomarker for neurological recovery, and facilitates monitoring of disease progression in the sub-acute post-injury phase." @default.
• W4302299867 created "2022-10-06" @default.
• W4302299867 creator A5012759534 @default.
• W4302299867 creator A5025235335 @default.
• W4302299867 creator A5043199243 @default.
• W4302299867 creator A5043954385 @default.
• W4302299867 creator A5060466587 @default.
• W4302299867 creator A5067496766 @default.
• W4302299867 creator A5069255744 @default.
• W4302299867 creator A5071676894 @default.
• W4302299867 creator A5073590053 @default.
• W4302299867 creator A5084187392 @default.
• W4302299867 date "2023-05-01" @default.
• W4302299867 modified "2023-09-30" @default.
• W4302299867 title "Trajectory of Serum Levels of Glial Fibrillary Acidic Protein Within Four Weeks Post-Injury Is Related to Neurological Recovery During the Transition from Acute to Chronic Spinal Cord Injury" @default.
• W4302299867 cites W1951724000 @default.
• W4302299867 cites W1965190536 @default.
• W4302299867 cites W1988868629 @default.
• W4302299867 cites W1994892513 @default.
• W4302299867 cites W2013092651 @default.
• W4302299867 cites W2014958031 @default.
• W4302299867 cites W2039486711 @default.
• W4302299867 cites W2040871722 @default.
• W4302299867 cites W2043369030 @default.
• W4302299867 cites W2052380760 @default.
• W4302299867 cites W2094482422 @default.
• W4302299867 cites W2118851633 @default.
• W4302299867 cites W2125001590 @default.
• W4302299867 cites W2135217992 @default.
• W4302299867 cites W2143900712 @default.
• W4302299867 cites W2149934533 @default.
• W4302299867 cites W2150947082 @default.
• W4302299867 cites W2153490715 @default.
• W4302299867 cites W2157203036 @default.
• W4302299867 cites W2169744240 @default.
• W4302299867 cites W2170622401 @default.
• W4302299867 cites W2360117167 @default.
• W4302299867 cites W2476303787 @default.
• W4302299867 cites W2550361609 @default.
• W4302299867 cites W2774486220 @default.
• W4302299867 cites W2807990765 @default.
• W4302299867 cites W2892938821 @default.
• W4302299867 cites W2903204522 @default.
• W4302299867 cites W2906242067 @default.
• W4302299867 cites W2913249489 @default.
• W4302299867 cites W2944160948 @default.
• W4302299867 cites W2973883831 @default.
• W4302299867 cites W3110272217 @default.
• W4302299867 cites W3199615250 @default.
• W4302299867 cites W4200282701 @default.
• W4302299867 cites W4221125598 @default.
• W4302299867 cites W4248686937 @default.
• W4302299867 doi "https://doi.org/10.1089/neu.2022.0326" @default.
• W4302299867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36200629" @default.
• W4302299867 hasPublicationYear "2023" @default.
• W4302299867 type Work @default.
• W4302299867 citedByCount "0" @default.
• W4302299867 crossrefType "journal-article" @default.
• W4302299867 hasAuthorship W4302299867A5012759534 @default.
• W4302299867 hasAuthorship W4302299867A5025235335 @default.
• W4302299867 hasAuthorship W4302299867A5043199243 @default.
• W4302299867 hasAuthorship W4302299867A5043954385 @default.
• W4302299867 hasAuthorship W4302299867A5060466587 @default.
• W4302299867 hasAuthorship W4302299867A5067496766 @default.
• W4302299867 hasAuthorship W4302299867A5069255744 @default.
• W4302299867 hasAuthorship W4302299867A5071676894 @default.
• W4302299867 hasAuthorship W4302299867A5073590053 @default.
• W4302299867 hasAuthorship W4302299867A5084187392 @default.
• W4302299867 hasConcept C118552586 @default.
• W4302299867 hasConcept C126322002 @default.
• W4302299867 hasConcept C204232928 @default.
• W4302299867 hasConcept C2778334475 @default.
• W4302299867 hasConcept C2780495277 @default.
• W4302299867 hasConcept C2780775167 @default.
• W4302299867 hasConcept C2781017439 @default.
• W4302299867 hasConcept C2781197716 @default.
• W4302299867 hasConcept C42219234 @default.
• W4302299867 hasConcept C55493867 @default.
• W4302299867 hasConcept C71924100 @default.
• W4302299867 hasConcept C86803240 @default.
• W4302299867 hasConceptScore W4302299867C118552586 @default.
• W4302299867 hasConceptScore W4302299867C126322002 @default.
• W4302299867 hasConceptScore W4302299867C204232928 @default.
• W4302299867 hasConceptScore W4302299867C2778334475 @default.
• W4302299867 hasConceptScore W4302299867C2780495277 @default.
• W4302299867 hasConceptScore W4302299867C2780775167 @default.
• W4302299867 hasConceptScore W4302299867C2781017439 @default.
• W4302299867 hasConceptScore W4302299867C2781197716 @default.
• W4302299867 hasConceptScore W4302299867C42219234 @default.
• W4302299867 hasConceptScore W4302299867C55493867 @default.
• W4302299867 hasConceptScore W4302299867C71924100 @default.
• W4302299867 hasConceptScore W4302299867C86803240 @default.
• W4302299867 hasIssue "9-10" @default.
• W4302299867 hasLocation W43022998671 @default.
• W4302299867 hasLocation W43022998672 @default.
• W4302299867 hasOpenAccess W4302299867 @default.
• W4302299867 hasPrimaryLocation W43022998671 @default.
• W4302299867 hasRelatedWork W1992812138 @default.

• next